EYPT January 2027 Options Begin Trading

EyePoint Inc. (EYPT) is being presented as an options trade idea: the $12.50 put (bid $3.00) implies a net purchase basis of $9.50 versus the current stock price of $13.36 and carries a 75% probability of expiring worthless, yielding a 24.00% return on cash (25.47% annualized). The $17.50 call (bid $2.50) as a covered-call sold against shares bought at $13.36 would produce a 49.70% total return if called at the January 2027 expiration, with a 35% chance of expiring worthless and an 18.71% premium boost (19.85% annualized). Implied volatility on both contracts is ~129% versus a trailing twelve‑month realized volatility of 72%; Stock Options Channel will track contract odds and histories on its site.

Analysis

Market structure: EyePoint (EYPT) is behaving like a small-cap, binary biotech where options markets are pricing large event risk — implied vol ~129% vs realized 72% (≈+57 vol points). Direct winners: option premium sellers and buy-and-hold investors willing to acquire shares at a discounted net basis ($9.50 if sold-to-open $12.50 put). Losers: convex call buyers who may be capped if a positive catalyst re-rates the stock above $17.50, and holders if a negative trial/financing shock forces dilutive capital raises.

Risk assessment: Tail risks are classic biotech shocks — negative FDA/clinical readouts or emergency dilution which could easily gap share price >40% lower within days (months for financing stress). Immediate (days) risk is assignment/gap; short-term (3–9 months) risk centers on trial readouts and cash runway; long-term (12–36 months) depends on commercialization/FDA outcomes. Hidden dependencies include low float/liquidity, borrow/margin needs on assignment, and model-driven “75% expire worthless” odds that assume log-normal moves which understate jump risk.

Trade implications: Favor structured premium-selling rather than naked exposure. Cash-secured $12.50 puts (net basis $9.50) are attractive if target acquisition at that price fits size limits; sell covered calls ($17.50) only if you are willing to cap upside at ~50% through Jan‑2027. Consider put-spreads or buy protective $10 puts to limit downside while harvesting rich IV.

Contrarian angles: The market may be underestimating upside from a positive readout—a binary positive could push shares well beyond $17.50, making covered-call sellers regretful. Conversely, IV-rich premium selling is historically profitable in absence of binary hits, but a single adverse event can wipe multiple months of YieldBoost. Treat EYPT as idiosyncratic event-risk, not a pure volatility play.

Key Decisions for Investors

• Establish a limited cash‑secured put program: sell-to-open Jan‑2027 EYPT $12.50 puts representing no more than 1–2% of portfolio notional (max 2 contracts per $1M AUM) to target an effective net basis of $9.50; roll or hedge if price falls below $11 within 30 days.
• If you already hold EYPT or want exposure, buy stock up to 1% weight and sell Jan‑2027 $17.50 covered calls to generate ~18.7% premium boost; cap position size so assigned upside loss above $17.50 is acceptable (pre-define exit at +50% total return).
• Prefer defined-risk premium strategies: sell-to-open put-spread ($12.50/$10) or sell $12.50 put and buy $10 put as hedge to limit max drawdown to ~+$1.50–$2.50 per share; only initiate if net credit ≥ $1.00 to preserve >8% immediate return on committed capital.
• Monitor 3 catalysts over next 90–270 days (trial readouts, cash runway/financing announcements, FDA filings). If cash runway extends >12 months post-announcement, widen put-selling size; if financing priced below $10 or negative readout, cut exposure immediately and buy protection.